4D pharma plc: Preliminary Safety and Clinical Observations From Its Phase I/II Study of MRx0518 in Combination With KEYTRUDA®

Corporate Breaking News

Home : 4D pharma plc: Preliminary Safety and Clinical Observations From Its Phase I/II Study of MRx0518 in Combination With KEYTRUDA®

Nov 06 2019	4D pharma plc: Preliminary Safety and Clinical Observations From Its Phase I/II Study of MRx0518 in Combination With KEYTRUDA®
LEEDS, England, Nov. 6, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live Biotherapeutics, today announced preliminary safety and clinical observations from an ongoing Phase I/II clinical trial, in collaboration with...


Source:https://www.prnewswire.com:443/news-releases/4d-pharma-plc-preliminary-safety-and-clinical-observations-from-its-phase-iii-study-of-mrx0518-in-combination-with-keytruda-300952341.html

Related News
» ChipMOS REPORTS THIRD QUARTER 2019 RESULTS » Wealth Dynamix annonce une croissance pour la septième année de suite grâce à son internationalisation et son innovation en matière de produits